Prognostic value of log odds of positive lymph nodes, lymph node ratio, and
SEER
colorectal signet ring cell carcinoma
log odds of positive lymph nodes
lymph node ratio
pN stage
Journal
Frontiers in surgery
ISSN: 2296-875X
Titre abrégé: Front Surg
Pays: Switzerland
ID NLM: 101645127
Informations de publication
Date de publication:
2022
2022
Historique:
received:
15
08
2022
accepted:
28
11
2022
entrez:
23
1
2023
pubmed:
24
1
2023
medline:
24
1
2023
Statut:
epublish
Résumé
Little attention has been paid in the prognosis of colorectal signet ring cell carcinoma (SRCC). This study aims to explore the predictive capacity of log odds of positive lymph nodes (LODDS), lymph node ratio (LNR), and pN stage in the prognosis of patients with colorectal SRCC. A retrospective cohort study was designed, and data were extracted from the Surveillance, Epidemiology and End Results (SEER) database. Data on demographic characteristics, clinicopathological features, and treatment were extracted. Outcomes were overall survival (OS) and cancer-specific survival (CSS). Association of LODDS, LNR, and pN stage with OS and CSS were explored using Cox proportional hazard model and Cox competing risk model, respectively, with results showing as hazard ratio and 95% confidence interval (CI). Predictive performance of LODDS, LNR, and pN stage in OS and CSS was assessed by calculating C-index. A total of 2,198 patients were included in this study. LODDS, LNR, and pN stage were associated with the OS and CSS of colorectal SRCC patients (all LODDS displayed a better predictive capacity in the OS and CSS than LNR and pN stage, indicating that LODDS may be effective to predict the prognosis of colorectal SRCC in the clinic.
Identifiants
pubmed: 36684239
doi: 10.3389/fsurg.2022.1019454
pmc: PMC9849566
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1019454Informations de copyright
© 2023 Hu, Jiang, Wu and Mao.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Surgery. 2018 Apr;163(4):784-788
pubmed: 29277386
Ann Surg Oncol. 2003 Jan-Feb;10(1):65-71
pubmed: 12513963
J Surg Oncol. 2022 Jun;125(8):1251-1259
pubmed: 35201620
Clin Cancer Res. 2004 Nov 1;10(21):7252-9
pubmed: 15534099
Chin J Cancer Res. 2020 Dec 31;32(6):778-793
pubmed: 33447000
Eur J Cancer. 2021 Nov;157:464-473
pubmed: 34649117
Curr Oncol. 2021 Dec 13;28(6):5356-5383
pubmed: 34940086
Cancers (Basel). 2020 Jun 11;12(6):
pubmed: 32545410
Updates Surg. 2018 Mar;70(1):23-31
pubmed: 29500795
Sci Rep. 2017 Mar 27;7:45334
pubmed: 28345614
Cancer Sci. 2020 Jun;111(6):2078-2092
pubmed: 32279400
World J Gastroenterol. 2014 Feb 28;20(8):1951-60
pubmed: 24587671
World J Clin Cases. 2021 Jan 6;9(1):24-35
pubmed: 33511169
Oncol Rep. 2020 Nov;44(5):2174-2184
pubmed: 33000262
BMC Gastroenterol. 2022 Apr 8;22(1):173
pubmed: 35395754
Gastroenterol Rep (Oxf). 2020 Dec 28;9(3):234-240
pubmed: 34316373
J Gastrointest Surg. 2019 May;23(5):1006-1014
pubmed: 30187336
Ann Surg Oncol. 2018 Jun;25(6):1454-1455
pubmed: 29616422
Cancer Manag Res. 2017 Nov 02;9:573-580
pubmed: 29138597
Eur J Cancer. 2005 Jan;41(2):272-9
pubmed: 15661553
Ann Transl Med. 2021 Apr;9(8):637
pubmed: 33987335
Am J Surg Pathol. 2002 Feb;26(2):179-89
pubmed: 11812939
Pathol Oncol Res. 2021 Jul 02;27:1609800
pubmed: 34276258